Analyst Price Targets — TNDM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 12:44 pm | — | Truist Financial | $27.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $27 from $24 at Truist |
| February 23, 2026 12:44 pm | — | Lake Street | $50.00 | $24.57 | TheFly | Tandem Diabetes upgraded to Buy from Hold at Lake Street |
| February 23, 2026 11:46 am | David Roman | Goldman Sachs | $28.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs |
| February 23, 2026 10:52 am | Matt Miksic | Barclays | $56.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $56 from $55 at Barclays |
| February 20, 2026 12:33 pm | — | Mizuho Securities | $22.00 | $18.52 | TheFly | Tandem Diabetes price target raised to $22 from $21 at Mizuho |
| February 20, 2026 12:10 pm | — | Stifel Nicolaus | $22.00 | $18.52 | TheFly | Tandem Diabetes price target raised to $22 from $20 at Stifel |
| February 20, 2026 12:09 pm | — | UBS | $22.00 | $18.52 | TheFly | Tandem Diabetes price target raised to $22 from $17 at UBS |
| February 20, 2026 11:37 am | Matt O'Brien | Piper Sandler | $21.00 | $18.52 | TheFly | Tandem Diabetes price target raised to $21 from $14 at Piper Sandler |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $20.00 | $19.11 | TheFly | Tandem Diabetes price target raised to $20 from $16 at Stifel |
| January 9, 2026 10:51 am | David Roman | Goldman Sachs | $25.00 | $22.50 | TheFly | Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs |
Latest News for TNDM
Tandem Diabetes Care (NASDAQ: TNDM) executives discussed recent operating performance and a broad set of strategic initiatives during a webcast event, emphasizing fourth-quarter execution improvements, an international sales model transition, upcoming product milestones, and a major shift in U.S. reimbursement through the pharmacy channel. Fourth-quarter momentum and margin expansion Management said the fourth…
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report) has been given an average recommendation of "Hold" by the nineteen ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, six have assigned a buy recommendation and one has
Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933,…
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report)'s share price rose 9% on Monday after Lake Street Capital upgraded the stock from a hold rating to a buy rating. Lake Street Capital now has a $50.00 price target on the stock. Tandem Diabetes Care traded as high as $27.92 and last traded at $26.7820.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TNDM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.